Reddit: MixedAttention: Watching

The Story

News Summary

Agenus presents Phase 1b data

Jul 6:Agenus announced three-year Phase 1b data for botensilimab and balstilimab in colorectal cancer.

Sentiment: 80% bullish / 20% neutral (early) → 60% bullish / 40% neutral (late)

Impact: The narrative shifted from initial excitement over trial results to a more measured outlook as further assessments are awaited.

Analyst ConsensusBuy (11 analysts)

Target: $7 avg

9 Buy · 2 Hold · 0 Sell

Signal

Bullish

Confidence

50%

Based on curated news sources (not retail comments)

Over the last 7 days: Agenus's promising clinical data for its cancer treatment suggests potential growth opportunities.

SentimentCautious Optimism

AnalysisHype

✓Presentation of three-year landmark Phase 1b data for botensilimab and balstilimab in colorectal cancer may indicate positive clinical progress.

Earnings

EPS: $0.79 → $-0.18 (2026 vs 2027)

▼ Expected to decline 123%

Explore

$AGEN